Benefits of Docetaxel for Metastatic Castration-Resistant Prostate Cancer Sudanese Patients and the Effective Number of Cycle and Dose (2013–2017)

Main Article Content

Mawahib Ahmed Elawad Abu Elgasim
Yousra Abdelmoniem Suleiman
Ehssan M. Elnazir Ahmed ELmubark
Alaa Albukhari Alrayah Abdalmahmoud
Sujood Abdelmoneim Mohmmed Babkeir
Rogaia Omer
Rayayan Yasin
Khalida Esmaiel Adam Abaker
Roa Osman Ahmed Babker
Anfal Abdalrhman Alryah
Thowibaah Abdalrhman Alzain

Abstract

Background: Prostate cancer remains the most common cancer in men worldwide and in Sudanese people. The initial treatment of choice for prostate cancer is androgen deprivation. If resistant to treatment, this leads to a state termed metastatic castration-resistant prostate cancer (mCRPC) which leads to the use of Docetaxel(Taxotere) which has been a mainstay of therapy for patients with mCRPC.

This study aimed to determine the optimal number of cycles of DOcetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer, through the evaluation of a number of parameters, such as performance status, prostate-specific antigen response and pain

Methods: Retrospective study of (60) metastatic castration-resistant prostate cancer (mCRPC) Sudanese patients who received Docetaxel plus prednisone (duration, 2013–2017).

Area; The Radiation and Isotopes Centre of Khartoum (RICK).Data collected by reviewing medical of records of patients confirmed (mCRPC).

Outcomes: Including: performance status, prostate-specific antigen (PSA) response and pain. According to this study we found that docetaxel has an effective role in the treatment of mCRPC patients with an optimal number of6–8 cycles every 3 weeks and with a dose of 75 mg

Conclusion: The benefits for using Docetaxel for mCRPC Sudanese patients: declined of PSA serum level, improvement of performance status and pain reduction. Effective optimal number of cycles 6 to 8 every 3 weeks and dose of 75 mg

Keywords:
Benefits, Docetaxel, mCRPC, Sudanese, men

Article Details

How to Cite
Elgasim, M. A. E. A., Suleiman, Y., Ahmed ELmubark, E. M. E., Abdalmahmoud, A. A. A., Babkeir, S. A. M., Omer, R., Yasin, R., Abaker, K. E. A., Babker, R. O. A., Alryah, A., & Alzain, T. (2019). Benefits of Docetaxel for Metastatic Castration-Resistant Prostate Cancer Sudanese Patients and the Effective Number of Cycle and Dose (2013–2017). International Research Journal of Oncology, 2(2), 1-9. Retrieved from http://journalirjo.com/index.php/IRJO/article/view/30100
Section
Original Research Article